All In Biotech

Drug Trial Radar · NCT02508389

A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of the Effects of GC4419 on Severe Oral Mucositis in Patients Receiving Cisplatin + Intensity-modulated Radiation Therapy (IMRT) for Locally Advanced Non-Metastatic Squamous Cell Carcinoma (SCC) of the Oral Cavity/Oropharynx

Last checked: Nov 20, 2026Latest source record: Sep 20, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 223 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

223

Actual

Start

Oct 12, 2015

Primary completion

Sep 18, 2017

Study completion Aug 29, 2019

Sponsor

Lead sponsor
Galera Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jul 24, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Supportive care
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the phase 2, GT-201 clinical study is to determine if GC4419 administered prior to intensity-modulated radiation therapy (IMRT) reduces the incidence, duration, and severity of radiation induced oral mucositis in patients who have been diagnosed with locally advanced, non-metastatic squamous cell carcinoma of the head and neck.

Conditions

  • Radiation Induced Oral Mucositis

Interventions

  • Low Dose GC4419: 30mg/dayDrug

    Low Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).

  • High Dose GC4419: 90mg/dayDrug

    High Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).

  • PlaceboDrug

    Placebo will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).

  • Intensity-Modulated Radiation TherapyRadiation

    Daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over approximately 7 weeks

  • CisplatinDrug

    Administered 80-100 mg/m2 once every three weeks for 3 doses or 30-40 mg/m2 once weekly for 6-7 doses. Substitution of other systemic agents due to related toxicities (i.e., carboplatin) would be evaluated to determine eligibility by the Medical Monitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Duration (in Days) of Radiation Induced Severe Oral Mucositis (OM) Per World Health Organization (WHO) CriteriaTime frame: From start of Intensity-modulated radiation therapy (IMRT) through 8 weeks follow-up, an average of 15 weeks

Locations

64 sites in 3 countries. Site status is shown where the registry gives one.

  • University of Arizona Cancer Center at Dignity Health St. Joseph's

    Phoenix, Arizona

  • University of Arizona

    Tucson, Arizona

  • Fowler Family Center for Cancer Care

    Jonesboro, Arkansas

  • University of Arkansas for Medical Sciences- Winthrop P. Rockefeller Cancer Institute

    Little Rock, Arkansas

  • VA Long Beach Healthcare System

    Long Beach, California

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California

  • Clinical Trials and Research Associates, Inc.

    Montebello, California

  • UC Irvine Chao Family Comprehensive Cancer Center

    Orange, California

  • Stanford Cancer Institute

    Stanford, California

  • St. Mary's Regional Cancer Center

    Grand Junction, Colorado

  • UConn Health School of Dental Medicine

    Farmington, Connecticut

  • Pasco Pinellas Cancer Center

    Holiday, Florida

  • Lakeland Regional Health Cancer Center

    Lakeland, Florida

  • UF Health Cancer Center at Orlando Health

    Orlando, Florida

  • Sacred Heart Medical Oncology Group

    Pensacola, Florida

  • Northwestern University

    Chicago, Illinois

  • University of Indianan, Goshen Center for Cancer Care

    Goshen, Indiana

  • Department of Radiation Oncology University of Iowa Hospitals & Clinics

    Iowa City, Iowa

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Ashland-Bellefonte Cancer Center

    Ashland, Kentucky

  • University of Kentucky, Albert B. Chandler Medical Center

    Lexington, Kentucky

  • University of Louisville Hospital, James Graham Brown Cancer Center

    Louisville, Kentucky

  • Tulane Cancer Center

    New Orleans, Louisiana

  • CHRISTUS Schumpert Cancer Treatment Center

    Shreveport, Louisiana

  • Baystate Regional Cancer Program

    Springfield, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Henry Ford Allegiance Health

    Jackson, Michigan

  • Lake Huron Medical Center

    Port Huron, Michigan

  • Ellis Fichel Cancer Center, University of Missouri

    Columbia, Missouri

  • Billings Clinic

    Billings, Montana

  • St. Vincent Frontier Cancer Center

    Billings, Montana

  • Renown Cancer Institute

    Reno, Nevada

  • Hunterdon Hematology Oncology, LLC Hunterdon Regional Cancer Center

    Flemington, New Jersey

  • Jersey Shore University Medical Center- Hackensack Meridian Health

    Neptune City, New Jersey

  • Montefiore Medical Center

    The Bronx, New York

  • East Carolina University, Leo W. Jenkins Cancer Center

    Greenville, North Carolina

  • Marion L. Shepard Cancer Center

    Washington, North Carolina

  • Wake Forest Health

    Winston-Salem, North Carolina

  • Ohio State University, James Cancer Center

    Columbus, Ohio

  • Toledo Clinic Cancer Center

    Toledo, Ohio

Showing 40 of 64 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.